Abstract
Development of a protective subunit vaccine against Leishmania spp. depends on antigens and adjuvants that induce appropriate immune responses. We evaluated a second generation polyprotein antigen (Leish-110f) in different adjuvant formulations for immunogenicity and protective efficacy against Leishmania spp. challenges. Vaccine-induced protection was associated with antibody and T cell responses to Leish-110f. CD4 T cells were the source of IFN-gamma, TNF, and IL-2 double- and triple-positive populations. This study establishes the immunogenicity and protective efficacy of the improved Leish-110f subunit vaccine antigen adjuvanted with natural (MPL-SE) or synthetic (EM005) Toll-like receptor 4 agonists.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic / pharmacology*
-
Animals
-
Antibodies, Protozoan / blood
-
Antibodies, Protozoan / immunology
-
Antigens, Protozoan / immunology*
-
CD4-Positive T-Lymphocytes / immunology
-
Epitope Mapping
-
Epitopes, T-Lymphocyte / immunology
-
Immunity, Cellular
-
Immunity, Humoral
-
Interferon-gamma / immunology
-
Interleukin-2 / immunology
-
Leishmaniasis Vaccines / immunology*
-
Leishmaniasis, Cutaneous / immunology
-
Leishmaniasis, Cutaneous / prevention & control*
-
Mice
-
Mice, Inbred BALB C
-
Recombinant Fusion Proteins / immunology
-
Toll-Like Receptor 4 / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / immunology
-
Vaccines, Subunit / immunology
Substances
-
Adjuvants, Immunologic
-
Antibodies, Protozoan
-
Antigens, Protozoan
-
Epitopes, T-Lymphocyte
-
Interleukin-2
-
Leishmaniasis Vaccines
-
Recombinant Fusion Proteins
-
Tlr4 protein, mouse
-
Toll-Like Receptor 4
-
Tumor Necrosis Factor-alpha
-
Vaccines, Subunit
-
Interferon-gamma